Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mediwound Ltd Ord Sh
(NQ:
MDWD
)
19.65
+0.46 (+2.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mediwound Ltd Ord Sh
< Previous
1
2
3
4
5
Next >
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
February 23, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
February 07, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
February 03, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know
December 30, 2022
Via
Benzinga
FDA Approves MediWound's NexoBrid For Burn Treatment
December 30, 2022
Via
Benzinga
Recap: MediWound Q2 Earnings
August 09, 2022
MediWound (NASDAQ:MDWD) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday
January 04, 2023
UBS cut Microsoft Corporation (NASDAQ: MSFT) price target from $300 to $250. UBS analyst Karl Keirstead downgraded the stock from Buy to Neutral. Microsoft shares fell 2% to $234.73 in pre-market...
Via
Benzinga
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
December 29, 2022
From
MediWound Ltd.
Via
GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
MediWound Posts Early Data From Non-Melanoma Skin Cancer Trial
July 11, 2022
Via
Benzinga
MediWound's EscharEx Shows Safe, Effective, Rapid Debridement Of Leg Ulcers
July 07, 2022
Via
Benzinga
MediWound: Q1 Earnings Insights
May 17, 2022
MediWound (NASDAQ:MDWD) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
December 23, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Strengthens European Presence of NexoBrid®
December 20, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
December 19, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
December 13, 2022
Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces a 1-for-7 Reverse Share Split
December 05, 2022
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Scheduled For November 15, 2022
November 15, 2022
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million.
Via
Benzinga
MediWound to Report Third Quarter 2022 Financial Results
November 03, 2022
Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Formation of Strategic Advisory Board
October 25, 2022
Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities
From
MediWound Ltd.
Via
GlobeNewswire
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
October 18, 2022
EscharEx’s promising results from the completed Phase 2 trials were highlighted
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
October 07, 2022
Gross Proceeds of $30.5 Million Raised
From
MediWound Ltd.
Via
GlobeNewswire
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
September 23, 2022
Gainers
Via
Benzinga
Dow Turns Higher; Crude Oil Rises 0.7%
September 22, 2022
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday.
Via
Benzinga
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
September 22, 2022
Gainers
Via
Benzinga
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher
September 22, 2022
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 03, 2022
Via
Benzinga
FDA Accepts MediWound's Refiling For Severe Thermal Burns Therapy For Review
August 03, 2022
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
May 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For May 17, 2022
May 17, 2022
Companies Reporting Before The Bell • On Holding (NYSE:ONON) is likely to report earnings for its first quarter.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.